Background. Conventional aortic valve replacement (AVR) remains the therapy of choice for many patients with severe aortic valve disease. The unique German Aortic Valve Registry (GARY) allows the comparison of contemporary outcomes of AVR with those of transcatheter AVRs. We report here real-world, all-comers outcomes of AVR, including combined AVR and coronary bypass grafting (AVRDCABG).
Methods. A total of 34,063 patients who received AVR (22,107 patients, 39% female; mean age 68.0 ± 11.3 years, mean logistic European System for Cardiac Operative Risk Evaluation, 8.6%) or AVRDCABG (11, 956 patients, 28% female; mean age 72.6 ± 7.8 years, mean logistic European System for Cardiac Operative Risk Evaluation, 10.7%) between 2011 and 2013 were analyzed and followed up to assess the 1-year outcome.
Results. In-hospital mortality was 2.3% for AVR and 4.1% for AVRDCABG. Other important outcome variables include stroke (AVR, 1.2%; AVRDCABG, 1.9%) and new pacemaker implantation (AVR, 4.4%; AVRD CABG, 3.6%). Survival at 1 year was 93.2% for AVR and 89.4% for AVRDCABG. Total stroke rates at 1 year were 1.6% for AVR and 2.0% AVRDCABG. Quality of life assessment indicated that most patients were in New York Heart Association Functional Classification I or II (AVR, 86%; AVRDCABG, 84%) and that they were satisfied with the overall postoperative course (AVR, 88%; AVRDCABG, 87%).
Conclusions. Contemporary surgical AVR yields excellent outcomes with low in-hospital mortality, a low overall complication rate, and good 1-year outcome for all risk groups. Accordingly, conventional AVR remains an important therapeutic option for many patients. is considered the therapy of choice for many patients with severe aortic valve disease according to common guidelines. During the past decade, however, transcatheter AVR (TAVR) has emerged as a minimally invasive alternative for high-risk patients [1] [2] [3] . The first randomized studies confirmed acceptable outcomes for certain selected high-risk and inoperable patients [4, 5] for both the transvascular and the transapical approach compared with conservative or surgical management. Meanwhile, the number of TAVR procedures performed in Europe, notably in Germany, has increased, and the Accepted for publication July 28, 2015.
growing experience as well as better valve prostheses and delivery systems have led to stable and improved TAVR results [6] . In the light of these circumstances, the German Aortic Valve Registry (GARY) was designed to allow the evaluation of contemporary outcomes of AVR and TAVR.
Several national European registries focus only on TAVR patients [7] [8] [9] . In the current literature, there is also a strong focus on this young technology, and recent advances in the conventional operation and the excellent hemodynamic performance of modern bioprostheses tend to be neglected [10, 11] . Current results from a large, multicenter, all-comers, all-surgical aortic valve disease patient population have not appeared in the literature to date.
Against this backdrop, the German Cardiac Society and the German Society for Thoracic and Cardiovascular Surgery inaugurated the GARY. The goal was to gather clinical information on all current transcutaneous and conventional aortic valve procedures, including patients being treated for coronary disease, currently being performed in Germany. Here we report the results of all patients who received conventional AVR or AVR and coronary artery bypass grafting (AVRþCABG) between 2011 and 2013 who were included in the GARY.
Patients and Methods

The GARY
The GARY was conceived to obtain a real-world picture of current practice for the treatment of aortic valve disease and to gather reliable data on the short-term and long-term outcomes of different aortic valve treatment strategies. Included are all patients undergoing interventional treatment (ie, AVR including the Ross procedure, aortic valve repair, aortic valvuloplasty, and transvascular and transapical TAVR). Currently more than 80,000 patients have signed informed consent preoperatively. The GARY protocol has been described in detail previously [12, 13] .
Statistics
Patients were divided into two groups: conventional AVR and AVRþCABG. In both groups, the results are presented separately for all patients in the group and for elective patients only, defined as nonurgent, nondecompensated, and nonendocarditis.
Categoric variables are presented in absolute values and percentages and continuously scaled variables as mean AE standard deviation. Time-to-event curves for death were calculated using Kaplan-Meier methods with the date of death estimated if the exact date was unknown. The European System for Cardiac Operative Risk Evaluation (EuroSCORE) was used to stratify risk groups.
Number of Centers and Patients
From 2011 to 2013, 49,660 patients from 95 centers were included in the registry; of whom, 34,063 patients (69%) underwent surgical AVR. The in-hospital outcome data refer to these patients.
The 1-year-follow-up has been completed for patients treated in 2011 and 2012. This includes 13,639 patients undergoing AVR and 7,382 patients undergoing AVRþCABG. Follow-up is 98.3% complete regarding the living status of those patients at 1 year.
To put the numbers for surgical AVR into the right context, some basic facts for TAVR patients included in the GARY during the same time period are given in Table 1 .
Results
Patient Characteristics
Mean age was 68.0 years for AVR patients and 72.6 years for AVRþCABG patients, and the mean logistic Euro-SCORE was 8.6% for AVR and 10.7% for AVRþCABG. As expected for an all-comers registry, patients of all age and risk groups were included. The relatively high TAVR penetration in Germany, however, can be attributed to the lower incidence of specific high-risk comorbidities in the surgically treated population compared with data from other registries [14] . All patient characteristics are summarized in Table 2 , and the valvular specifications are reported in Table 3 .
In-Hospital Mortality Rate
The in-hospital mortality rate was 1.8% for elective AVR (2.3% for all AVR patients) and was 3.3% for elective AVRþCABG (4.1% for all AVRþCABG patients). The inhospital mortality rate stratified by age and risk profile is reported in Table 4 . The total numbers in some subgroups are low, and therefore, the results must be interpreted with caution. The mortality rate is lower than previously reported for the low-risk groups (eg, 1.2% for patients aged <70 years old and logistic EuroSCORE <10%) and does not depend on age alone.
Other In-Hospital Outcomes
The stroke rate was as low as expected, at 1.0% for elective AVR patients and 1.9% for AVRþCABG patients. Approximately 6% of the patients had new-onset atrial fibrillation, and 4% needed a new-onset pacemaker implantation. Other complications are summarized in Table 5 .
One-Year Survival
At the 1-year follow-up interview, 92.5% of the elective AVR patients were alive, 6.0% were known to have died, and the status was unknown for 1.5%; and for elective AVRþCABG, 88.8% were alive, 9.7% had died, and status was unknown for 1.7% (Table 6 ). Figure 1 depicts the cumulative mortality for the four subgroups.
Complications During Follow-Up
The overall complication rate during the first year after the operation was low, as reported by the interviewed patients. The total stroke rate (including in-hospital strokes) was between 1.4% and 2.0%. About one-third of the patients were readmitted to a hospital during the first year, but this was due to the original procedure only in a small proportion. All other complications are reported in Table 7 .
Quality of Life
Almost 85% of the interviewed patients in all groups were in New York Heart Association Functional Classification I or II; that is, more than 92% were in better health or at least had the same clinical condition than before the operation (Table 7) . This clinical status is in accordance with the subjective evaluation of the patients who described their general status of heath as better or at least the same as before the operation (Fig 2) , and thus, only a small number of patients (less than 3.5%) were not satisfied at 1 year (Fig 3) .
Time Dependence
A slight trend to healthier patients was observed during the surveillance period. However, the differences were marginal, reflecting that TAVR was available and fully reimbursed since 2009 in Germany. By 2011 TAVR had already reached a high penetration. Interestingly, the percentage of implanted sutureless valves remained very low. This technology obviously was not able to gain ground (Table 8) .
Comment
The spectrum of therapeutic options for aortic valve disease has widened during the past decade. In parallel with a relatively stable number of conventional surgical procedures on the aortic valve, an exponential growth in the rate of catheter-based valve implantations has been observed. This has occurred particularly in countries with no restrictions on health care cost reimbursement during the past 5 years; accordingly, these procedures account for 30% to 40% of all AVRs in Germany. Today, TAVR has become a routine clinical procedure for patients at high risk for conventional surgical procedures. This has led to a 50% increase overall in patients treated for aortic stenosis, whereas absolute numbers of conventional surgical AVR remain almost the same as before the TAVR era.
Several clinical trials have addressed this development. The randomized Placement of Aortic Transcatheter Valve (PARTNER B) trial demonstrated superiority of TAVR over conventional therapy in inoperable patients [4] , whereas noninferiority was observed compared with conventional AVR in patients at high risk for surgery (PARTNER A) [5] . A second randomized comparison even showed a higher survival rate with TAVR in patients with an increased risk for surgical AVR after 1 year [6] .
Tamburino and colleagues [15] recently published a comparison of the 1-year outcomes of TAVR vs surgical AVR. In this retrospective study with a relatively small number of patients, no differences between the groups concerning the primary end point of major adverse cardiac and cerebrovascular events were found after risk adjustment. However, the 30-day mortality rate in the surgical group was unusually high, whereas the late mortality rate in the TAVR group was higher [15] .
Presently, there is an ongoing discussion on potential risk creep with TAVR, challenging conventional [17] ). In these discussions, results for the conventional operation are often extrapolated from older studies because of a lack of contemporary real-world outcome data. However, a large number of publications on TAVR are available that demonstrate improving results in that field. This can lead to distortions in the overall picture of AVR and was one of the reasons for the inauguration of the GARY. Although randomized clinical trials offer the best evidence for the effectiveness of any new therapeutic approach, one has to keep in mind that patient inclusion into such trials is usually quite selective. Routine clinical decision making needs to focus on all-comers outcomes, most importantly because physicians are confronted with an all-comers population and not selected patient groups in everyday clinical practice. Therefore, an allcomers registry such as the GARY provides a realistic picture of clinical results and can thus reliably guide future clinical decision making. A similar data analysis drawn from the comprehensive The Society of Thoracic Surgeons database was published by Thourani and colleagues [14] earlier this year showed similar outcomes in the low-risk groups. The lower mortality rate for the intermediate-risk and high-risk patients in the GARY might be explained with the already very high transcatheter aortic valve implantation penetration in Germany. The data shown here clearly demonstrate that conventional surgical techniques can be applied to all risk groups with very good outcomes that are similar to or better than those reported in recent publications [10, 11] . The low mortality rates and low overall complication rates support the position that conventional AVR is and remains the gold standard for patients with aortic stenosis who are at low and intermediate risk.
Limitations
The major limitation of this study is that patient inclusion is voluntary rather than mandatory. Compensating for this limitation is that the overall patient number is high enough to yield some meaningful results stemming from contemporary practice.
Owing to patient selection, a direct comparison of these results with results from other registries or clinical series should be made only with caution. In addition, it should be considered that the good outcome of conventional AVR was achieved in an environment where most of the high-risk patients were scheduled for TAVR by the heart teams. Nonetheless, the GARY and the surgical results of this study deliver a solid basis for further discussions in this interesting and rapidly evolving field.
Conclusions
Surgical AVR resulted in a low in-hospital mortality rate and a low overall complication rate and in good 1-year outcomes for all risk groups. These all-comers registry data therefore clearly indicate that conventional AVR remains the therapy of choice for lower-risk patients with aortic stenosis.
